Dual-Modified Novel Biomimetic Nanocarriers Improve Targeting and Therapeutic Efficacy in Glioma

Fu, Shiyao; Liang, Meng; Wang, Yuli; Cui, Lin; Gao, Chun‐Hong; Chu, Xiaoyang; Liu, Qianqian; Yang, Feng; Gong, Wenbin; Yang, Meiyan; Li, Zhiping; Yang, Chunrong; Xie, Xiangyang; Yang, Yang; Gao, Chunsheng

doi:10.1021/acsami.8b18664

Cited by 125 publications

(103 citation statements)

References 36 publications

Supporting

Mentioning

101

Contrasting

Order By: Relevance

“…Moreover, PLGA's acidic by-products in degradation may render them inappropriate for extended use in in brain (Yang, 2010). Compared to PLGA nanoparticles, nanostructured lipid carrier based on natural lipids are more biocompatible, since they need not use of organic solvents during their fabrication and their degradation products may not influence the extracellular/intracellular environment (Fu et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

Neuronal mitochondria-targeted therapy for Alzheimer’s disease by systemic delivery of resveratrol using dual-modified novel biomimetic nanosystems

Yang

Chu

Cui³

et al. 2020

Drug Delivery

Self Cite

View full text Add to dashboard Cite

Reactive oxygen species (ROS)-induced neuronal mitochondrial dysfunction is a key pathologic factor in sporadic Alzheimer's disease (AD). Neuronal mitochondria have been proposed to be a promising therapeutic target for AD, especially for the failures of phase III clinical trials on conventional amyloidb (Ab) targeted therapy. However, the efficient intravenous delivery of therapeutic agents to neuronal mitochondria in the brain remains a major challenge due to the complicated physiological environment. Recently, biomaterials-based nanomedicine has been widely investigated for the treatment of AD. Herein, we devised a strategy for functional antioxidant delivery to neuronal mitochondria by loading antioxidants into red blood cell (RBC) membrane-coated nanostructured lipid carriers (NLC) bearing rabies virus glycoprotein (RVG29) and triphenylphosphine cation (TPP) molecules attached to the RBC membrane surface (RVG/TPP NPs@RBCm). With the advantage of suitable physicochemical properties of NLC and unique biological functions of the RBC membrane, RVG/TPP NPs@RBCm are stabilized and enabled sustained drug release, providing improved biocompatibility and long-term circulation. Under the synergistic effects of RVG29 and TPP, RVG/TPP NPs@RBCm can not only penetrate the blood-brain barrier (BBB) but also target neuron cells and further localize in the mitochondria. After encapsulating Resveratrol (RSV) as the model antioxidant, the data demonstrated that RVG/TPP-RSV NPs@RBCm can relieve AD symptoms by mitigating Ab-related mitochondrial oxidative stress both in vitro and in vivo. The memory impairment in APP/PS1 mice is significantly improved following the systemic administration of RVG/TPP-RSV NPs@RBCm. In conclusion, intravenous neuronal mitochondria-targeted dual-modified novel biomimetic nanosystems are a promising therapeutic candidate for ROS-induced mitochondrial dysfunction in AD.

show abstract

Section: Introductionmentioning

confidence: 99%

Neuronal mitochondria-targeted therapy for Alzheimer’s disease by systemic delivery of resveratrol using dual-modified novel biomimetic nanosystems

Yang

Chu

Cui³

et al. 2020

Drug Delivery

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recently, RBC membrane-covered solid lipid NPs were synthetized and functionalized with T7 and NGR peptides absorbed on their surface [70]. Loading these NPs with vinca alkaloid vincristine (VCR), showed anti-glioma effectiveness both in vitro and in vivo.…”

Section: Rbc Membrane-covered Npsmentioning

confidence: 99%

Biomimetic Nanocarriers for Cancer Target Therapy

et al. 2020

View full text Add to dashboard Cite

Nanotechnology offers innovative tools for the design of biomimetic nanocarriers for targeted cancer therapy. These nano-systems present several advantages such as cargo’s protection and modulation of its release, inclusion of stimuli-responsive elements, and enhanced tumoral accumulation. All together, these nano-systems suffer low therapeutic efficacy in vivo because organisms can recognize and remove foreign nanomaterials. To overcome this important issue, different modifications on nanoparticle surfaces were exploited in order to reach the desired therapeutic efficacy eliciting, also, the response of immune system against cancer cells. For this reason, more recently, a new strategy involving cell membrane-covered nanoparticles for biomedical application has been attracting increasing attention. Membranes from red blood cells, platelets, leukocytes, tumor, and stem cells, have been exploited as biomimetic coatings of nanoparticles for evading clearance or stimulated immune system by maintaining in the same way their targeting capability. In this review, the use of different cell sources as coating of biomimetic nanocarriers for cancer therapy is discussed.

show abstract

“…The CD13 receptor also plays a crucial role in promoting angiogenesis in receptor-mediated anti-angiogenic therapy. Over recent years, D WSW-and NGR-modified nanocarriers have been developed (23)(24)(25)(26).…”

Section: Introductionmentioning

confidence: 99%

Dual-Target Peptide-Modified Erythrocyte Membrane-Enveloped PLGA Nanoparticles for the Treatment of Glioma

Cui

Sun²,

Hao³

et al. 2020

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

Penetration of the blood-brain barrier (BBB) and the blood-brain tumor barrier (BBTB) remains a significant challenge for the delivery of drugs in the treatment of glioma. Therefore, the development of targeted preparations with the ability to penetrate the BBB and BBTB, and target gliomas, is an important approach if we are to improve the efficacy of glioma treatment. In the current study, an active targeting preparation based on PLGA nanoparticles coated with erythrocyte membranes (RBCNPs) and dual-modified with D WSW and NGR peptide ligands (D WSW/NGR-RBCNPs). Euphorbia factor L1 (EFL1) extracted from euphorbiae semen was used as the model drug. The final nanoparticles were characterized by in vivo and in vitro tests. In vitro results showed that EFL1-loaded D WSW/NGR-RBCNPs were taken up by cells and had the ability to penetrate the BBB and BBTB and produce cytotoxic effects. Furthermore, in vivo studies in mice showed that when injected intravenously, these specialized NPs could enter the brain, target tumor tissue, and significantly extend life span. The results showed that dualtargeting EFL1-loaded D WSW/NGR-RBCNPs have significant potential as a nanotherapeutic tool for the treatment of brain glioma.

show abstract

Dual-Modified Novel Biomimetic Nanocarriers Improve Targeting and Therapeutic Efficacy in Glioma

Cited by 125 publications

References 36 publications

Neuronal mitochondria-targeted therapy for Alzheimer’s disease by systemic delivery of resveratrol using dual-modified novel biomimetic nanosystems

Neuronal mitochondria-targeted therapy for Alzheimer’s disease by systemic delivery of resveratrol using dual-modified novel biomimetic nanosystems

Biomimetic Nanocarriers for Cancer Target Therapy

Dual-Target Peptide-Modified Erythrocyte Membrane-Enveloped PLGA Nanoparticles for the Treatment of Glioma

Contact Info

Product

Resources

About